Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)
|ClinicalTrials.gov Identifier: NCT00379418|
Recruitment Status : Completed
First Posted : September 21, 2006
Last Update Posted : September 12, 2013
TITLE: Anti-Ischemic effects of Abciximab(Reopro)
PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).
INTERVENTION: Heparin vs. heparin + abciximab during PCI
PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow.
- 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.
- Measurement of blood flow in selected suitable patients
- 10 minute questionnaire before discharge and on visit on day 28.
|Condition or disease||Intervention/treatment|
|Coronary Artery Disease||Drug: Abciximab|
|Study Type :||Observational|
|Actual Enrollment :||220 participants|
|Official Title:||Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00379418
|United States, Georgia|
|Atlanta VA Medical Center|
|Atlanta, Georgia, United States, 30033|
|Emory University Hospital|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Arshed A Quyyumi, M.D.||EUH|